🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsGIP receptor pharmacology — my results so far Page 2

GIP receptor pharmacology — my results so far

DoseLogDan Mon, Jul 21, 2025 at 12:05 AM 12 replies 1,512 viewsPage 2 of 3
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Jul 21, 2025 at 3:06 AM#6
Dr.SurgeonPGH said:
Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

Last edited: Jul 21, 2025 at 6:06 AM
39 9steve_okc, dave_SLC, FDA_TrackerJim and 36 others
Reply Quote Save Share Report
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Jul 21, 2025 at 4:17 AM#7

Adding the numbers, since they settle part of this. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.

Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

38 8MikeFit_NJ, InsuranceTom, WendyG_ATL and 35 others
Reply Quote Save Share Report
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
Jul 21, 2025 at 5:28 AM#8
kate.chem said:
The "tirzepatide is simply better" summary irritates me.

Coming at kate.chem’s question from a different direction. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

That is the short version; the long version is somebody else's post.

37 7BrianDallas92, labquiet_amy, emily_PDX and 34 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
maria_elpaso
Member
312
1,456
Sep 2024
El Paso, TX
Jul 21, 2025 at 6:39 AM#9

A narrower follow-up, since the general answer is now clear:

How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?

36 6HPLC_Greg, LibrarianMeg, bri_stats and 33 others
Reply Quote Save Share Report
DoseLogDan
Member
201
567
Feb 2025
Montana
Jul 21, 2025 at 12:21 PM#10

Closing the loop on my own question.

Update: the eight-week restart pattern people described is exactly what happened. I nearly abandoned it at week five.

Last edited: Jul 21, 2025 at 1:21 PM
38 11carlos_SATX, sophie_paris, mel_PDX and 35 others
Reply Quote Save Share Report

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register